Breedlove Robert Charles 4
4 · Phathom Pharmaceuticals, Inc. · Filed Mar 3, 2026
Research Summary
AI-generated summary of this filing
Phathom (PHAT) Principal Accounting Officer Robert Breedlove Receives Awards
What Happened
- Robert Charles Breedlove, Phathom's Principal Accounting Officer, was granted/issued equity on Feb 27, 2026 and also surrendered shares to cover withholding. He was granted 13,000 restricted stock units (RSUs) (award code A) and received 2,790 shares issued upon vesting of previously granted performance stock units (PSUs). To satisfy tax withholding, Breedlove surrendered a total of 1,378 shares (964 shares and 414 shares) which were treated as dispositions at $12.56 per share, generating proceeds of $12,108 and $5,200 respectively (total ~$17,308). The primary activity here is an equity award/vesting, with the share surrenders representing tax withholding rather than an open-market sale.
Key Details
- Transaction date: February 27, 2026; Form 4 filed March 3, 2026 (filed within the typical two-business-day window).
- Grants/issuances: 13,000 RSUs (new grant) and 2,790 shares issued upon PSU vesting.
- Tax withholding dispositions: 964 shares and 414 shares surrendered at $12.56 per share (total surrendered = 1,378 shares; total ~$17,308).
- Shares owned after the transaction: not specified in the provided filing excerpt.
- Footnotes of note:
- F1: The 13,000 RSUs vest 1/3 on each of the first three anniversaries of Feb 27, 2026, subject to continued service; each RSU equals one share on vesting.
- F2: The 2,790 shares represent PSUs granted Feb 27, 2025 that were determined to have met performance criteria and vested Feb 27, 2026.
- F3/F4: The surrendered shares were delivered to the issuer to satisfy the issuer's tax withholding obligations (i.e., tax withholding, not an open-market sale).
- Transaction codes: A = Award/Grant; F = tax withholding disposition.
Context
- This filing shows equity compensation being granted and vested (a common retention/compensation mechanism). The surrendered shares solely cover tax obligations and do not necessarily indicate a decision to sell shares for investment reasons. For RSUs, vesting is time-based (1/3 per year); for PSUs, vesting depended on prior performance metrics that were determined satisfied.
Insider Transaction Report
Form 4
Breedlove Robert Charles
Principal Accounting Officer
Transactions
- Award
Common Stock
[F1]2026-02-27+13,000→ 60,068 total - Award
Common Stock
[F2]2026-02-27+2,790→ 62,858 total - Tax Payment
Common Stock
[F3]2026-02-27$12.56/sh−964$12,108→ 61,894 total - Tax Payment
Common Stock
[F4]2026-02-27$12.56/sh−414$5,200→ 61,480 total
Holdings
- 6,945.4(indirect: By 401(k))
Common Stock
Footnotes (4)
- [F1]Represents restricted stock units ("RSUs") granted on February 27, 2026. 1/3 of the total number of RSUs granted vest on each of the first three anniversaries of February 27, 2026, the vesting commencement date, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
- [F2]Represents shares issued upon vesting of performance stock units granted to the reporting person on February 27, 2025 based on the achievement of performance criteria determined to be satisfied on February 27, 2026.
- [F3]Represents shares underlying the performance stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.
- [F4]Represents shares underlying RSUs that were surrendered by the reporting person to the Issuer upon vesting of such RSU in satisfaction of the Issuer's tax withholding obligation.
Signature
/s/ Robert Charles Breedlove|2026-03-03